Tislelizumab: an effective treatment option for early-stage triple-negative breast cancer

Transl Breast Cancer Res. 2023 Nov 22:5:5. doi: 10.21037/tbcr-23-39. eCollection 2024.

Author

Zhigang Yu¹

Affiliation

¹ Department of Breast Surgery, The Second Hospital of Shandong University, Jinan, China.

No abstract available

Keywords: Immune-checkpoint inhibitors (ICIs); cTRIO; tislelizumab; triple-negative breast cancer (TNBC).

Publication types

Editorial